Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

• Prif Awduron: Brendan Bender (Awdur), Chi‐Chung Li (Awdur), Mathilde Marchand (Awdur), David C. Turner (Awdur), Feifei Li (Awdur), Shweta Vadhavkar (Awdur), Bei Wang (Awdur), Rong Deng (Awdur), James Lu (Awdur), Jin Jin (Awdur), Chunze Li (Awdur), Shen Yin (Awdur), Michael Wei (Awdur), Pascal Chanu (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2024-06-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Mosunetuzumab (Mosun) is a CD20xCD3 T‐cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step‐up dose regimen of 1/2/60/30 mg IV is designed to mitigate cytokine release syndrome (CRS) and maximize efficacy in early cycles. A population pha...